Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699836 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC
A Phase 2 study of Metastatic Colorectal Cancer (mCRC), sponsored by CytoDyn.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT06699836 is a Phase 2 study of Metastatic Colorectal Cancer (mCRC) that is actively recruiting participants, run by CytoDyn. The registered enrollment target is 60 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT06699836, a Phase 2 study of Metastatic Colorectal Cancer (mCRC), is actively recruiting participants, sponsored by CytoDyn.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. 2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab.
Conditions Studied
Interventions
- DRUG 350 mg leronlimab
- DRUG 700 mg leronlimab
Study Locations (6)
California
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Pacific Hematology Oncology Associates - San Francisco
Kentucky
- Norton Cancer Institute, Brownsboro Hospital Campus - Louisville
Nebraska
- University of Nebraska Medical Center - Omaha
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- Summit Cancer Center - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699836
The ClinicalTrials.gov registry entry for NCT06699836 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer (mCRC) appearing as the primary indexed condition, and to 2 interventions - of which 350 mg leronlimab is the first listed.
NCT06699836 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Kentucky, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06699836 about?
NCT06699836 is a clinical study titled "A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC". This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed o...
What is the current status of trial NCT06699836?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-06-16. Estimated completion is 2028-03.
What conditions does trial NCT06699836 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer (mCRC).
What interventions are being tested in trial NCT06699836?
The interventions under investigation include: 350 mg leronlimab (DRUG), 700 mg leronlimab (DRUG).
Who is sponsoring clinical trial NCT06699836?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699836 being conducted?
This trial has 6 study locations across California, Kentucky, Nebraska, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer (mCRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.